Treprostinil (Orenitram) vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Orenitram)
Marketed by United Therapeutics
NCT00325403 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.
Reported efficacy
Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)
Result source: NCT00325403
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
NCT03399604 · Phase 3 · completed
The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)
Result source: NCT03399604
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Treprostinil (Orenitram): 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Orenitram) | Treprostinil (Yutrepia, Liquidia) |
|---|---|---|
| Dropout rate | 21.9%a NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results42.1% NCT01560637 · Phase 3 · registry result, not featured evidence 76.7% NCT01027949 · Phase 3 · registry result, not featured evidence 57.2% NCT01560624 · Phase 3 · registry result, not featured evidence 12.1% NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result24%LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Discontinued due to AEs | —a NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results13.4% NCT01560637 · Phase 3 · registry result, not featured evidence 19.2% NCT01027949 · Phase 3 · registry result, not featured evidence — NCT01560624 · Phase 3 · registry result, not featured evidence — NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Serious AEs | 17.9%a NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results43.8% NCT01560637 · Phase 3 · registry result, not featured evidence 61.2% NCT01027949 · Phase 3 · registry result, not featured evidence 33.5% NCT01560624 · Phase 3 · registry result, not featured evidence 18.4% NCT00325442 · Phase 3 · registry result, not featured evidence 50%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 33.3%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 12.4%LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Most frequent reported AEs | a headache 62.9% (placebo 19.5%) diarrhea 30.5% (placebo 15.6%) nausea 29.8% (placebo 18.2%) NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more resultsheadache 69.8% diarrhoea 66.2% flushing 42.8% NCT01560637 · Phase 3 · registry result, not featured evidence headache 78.1% diarrhoea 66.2% nausea 56.5% NCT01027949 · Phase 3 · registry result, not featured evidence headache 74.9% (placebo 34.9%) diarrhoea 69.4% (placebo 28.5%) flushing 44.5% (placebo 7.8%) NCT01560624 · Phase 3 · registry result, not featured evidence headache 86.2% (placebo 36.9%) nausea 64.4% (placebo 34.1%) diarrhea 60.9% (placebo 27.3%) NCT00325442 · Phase 3 · registry result, not featured evidence headache 100% diarrhoea 75% nausea 75% NCT02276872 · Phase 2 · registry result, not featured evidence · combination | cough 33.9% headache 19% upper respiratory tract infection 14.9% NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Orenitram)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Orenitram)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape